

## Biosimilar medicines authorised via the EMA

Last updated 20/03/2019



[www.biosimilars-nederland.nl](http://www.biosimilars-nederland.nl)

Biosimilar	CHMP positive opinion	Indication	Marketing Authorisation Holder	Authorised*
Adalimumab (Idacio®)	jan.-19	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Fresenius Kabi	Awaiting authorisation
Adalimumab (Kromea®)	jan.-19	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Fresenius Kabi	Awaiting authorisation
Bevacizumab (Zirabev®)	dec.-18	Colorectal Neoplasms Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Uterine Cervical Neoplasms	Pfizer	feb.-19
Trastuzumab (Ogivri®)	okt.-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Mylan	dec.-18
Pegfilgrastim (Fulphila®)	sep.-18	Neutropenia	Mylan	nov.-18
Pegfilgrastim (Pelmeg®)	sep.-18	Neutropenia	Cinfa Biotech S.L.	nov.-18
Pegfilgrastim (Ziextenzo®)	sep.-18	Neutropenia	Sandoz	nov.-18
Pegfilgrastim (Pelgraz®)	jul.-18	Neutropenia	Accord Healthcare	sep.-18
Pegfilgrastim (Udenyca®)	jul.-18	Neutropenia	ERA Consulting	sep.-18
Adalimumab (Hulio®)	jul.-18	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Mylan	sep.-18
Adalimumab (Halimatoz®)	mei-18	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis	Sandoz	jul.-18
Adalimumab (Hyrimoz®)	mei-18	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Sandoz	jul.-18

## Biosimilar medicines authorised via the EMA



Last updated 20/03/2019

[www.biosimilars-nederland.nl](http://www.biosimilars-nederland.nl)

Biosimilar	CHMP positive opinion	Indication	Marketing Authorisation Holder	Authorised*
Adalimumab (Hefiya®)	mei-18	Juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis	Sandoz	jul.-18
Trastuzumab (Trazimera®)	mei-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Pfizer	jul.-18
Trastuzumab (Kanjinti®)	mrt.-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Amgen	mei-18
Infliximab (Zessly®)	mrt.-18	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Sandoz	mei-18
Insulin glargine (Semglee®)	jan.-18	Diabetes Mellitus	Mylan	mrt.-18
Trastuzumab (Herzuma®)	dec.-17	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Celltrion	feb.-18
Bevacizumab (Mvasi®)	nov.-17	Fallopian tube neoplasms, Non-Small-Cell Lung Carcinoma, ovarian neoplasms, Renal Cell Carcinoma, Peritoneal Neoplasms, Breast Neoplasms	Amgen	jan.-18
Trastuzumab (Ontruzant®)	sep.-17	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Samsung Bioepis	nov.-17
Adalimumab (Imraldi®)	jun.-17	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis	Samsung Bioepis	aug.-17
Insulin Lispro (Insulin lispro Sanofi®)	may-17	Diabetes mellitus	Sanofi	jul.-17
Rituximab (Blitzima®)	may-17	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis and microscopic polyangiitis.	Celltrion	jul.-17
Rituximab (Rituzena®)	may-17	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis and microscopic polyangiitis.	Celltrion	jul.-17
Rituximab (Ritemvia®)	may-17	Non-Hodgkin's lymphoma, granulomatosis with polyangiitis and microscopic polyangiitis.	Celltrion	jul.-17
Etanercept (Erelzi®)	apr.-17	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, paediatric plaque psoriasis.	Sandoz	jun.-17
Rituximab (Riximyo®)	apr.-17	Non-Hodgkin's lymphoma, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Sandoz	jun.-17

## Biosimilar medicines authorised via the EMA

Last updated 20/03/2019



[www.biosimilars-nederland.nl](http://www.biosimilars-nederland.nl)

Biosimilar	CHMP positive opinion	Indication	Marketing Authorisation Holder	Authorised*
Rituximab (Rixathon®)	apr.-17	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Sandoz	jun.-17
Adalimumab (Amgevita®)	jan.-17	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis	Amgen	mrt.-17
Rituximab (Truxima®)	dec.-16	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Celltrion	feb.-17
Teriparatide (Movymia®)	nov.-16	Osteoporosis	STADA Arzneimittel	jan.-17
Teriparatide (Terrosa®)	nov.-16	Osteoporosis	Gedeon Richter	jan.-17
Enoxaparin (Inhixa®)	jul.-16	Prophylaxis of venous thromboembolic disease, deep vein thrombosis, pulmonary embolism, acute coronary syndrome and extra corporeal haemodialysis	Techdow	sep.-16
Enoxaparin (Thorinane®)	jul.-16	Prophylaxis of venous thromboembolic disease, deep vein thrombosis, pulmonary embolism, acute coronary syndrome and extra corporeal haemodialysis	Pharmathen	sep.-16
Infliximab (Flixabi®)	mrt.-16	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Samsung Bioepis	mei-16
Etanercept (Benepali®)	nov.-15	Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis	Samsung Bioepis	jan.-16
Filgrastim (Accofil®)	jul.-14	Neutropenia	Accord Healthcare	sep.-14
Insulin glargine (Abasaglar®)	jun.-14	Diabetes Mellitus	Eli Lilly	sep.-14
Follitropin alfa (Bemfola®)	jan.-14	Anovulation	Finox	mrt.-14
Filgrastim (Grastofil®)	jul.-13	Neutropenia	Apotex	okt.-13
Infliximab (Remsima®)	jun.-13	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Celltrion	sep.-13
Infliximab (Inflectra®)	jun.-13	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Hospira	sep.-13
Follitropin alfa (Ovaleap®)	aug.-13	Anovulation	Teva	sep.-13

## Biosimilar medicines authorised via the EMA

Last updated 20/03/2019



[www.biosimilars-nederland.nl](http://www.biosimilars-nederland.nl)

Biosimilar	CHMP positive opinion	Indication	Marketing Authorisation Holder	Authorised*
Filgrastim (Nivestim®)	mrt.-10	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Hospira/Pfizer	jun.-10
Filgrastim (Filgrastim Hexal®)	nov.-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Hexal	feb.-09
Filgrastim (Zarzio®)	nov.-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Sandoz	feb.-09
Filgrastim (Ratiograstim®)	jul.-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Ratiopharm	sep.-08
Filgrastim (Tevagrastim®)	jul.-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Teva	sep.-08
Epoetin zeta (Retacrit®)	oct-07	Anaemia, kidney Failure, chronic blood transfusion, autologous cancer	Hospira	dec.-07
Epoetin zeta (Silapo®)	oct-07	Anaemia, kidney Failure, chronic blood transfusion, autologous cancer	Stada	dec.-07
Epoetin alfa (Abseamed®)	okt.-08	Anaemia, chronic renal failure, cancer	Medice	aug.-07
Epoetin alfa (Binocrit®)	jun.-07	Anaemia, chronic renal failure, cancer	Sandoz	aug.-07
Epoetin alfa (Epoetin Alfa Hexal®)	jun.-07	Anaemia, chronic renal failure, cancer	Hexal	aug.-07
Somatropin (Omnitrope®)	jun.-03	Growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency, small for gestational age	Sandoz	apr.-06